Coherus Oncology Inc (NAS:CHRS)
$ 1.4487 -0.0013 (-0.09%) Market Cap: 223.46 Mil Enterprise Value: 96.41 Mil PE Ratio: 0.87 PB Ratio: 2.84 GF Score: 42/100

Q4 2019 Coherus BioSciences Inc Earnings Call Transcript

Feb 27, 2020 / 09:30PM GMT
Release Date Price: $19.19 (-5.84%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Coherus BioSciences 2019 Fourth Quarter Earnings Conference Call. My name is May, and I will be your conference operator for the call today. (Operator Instructions) And as a reminder, this conference call is being recorded.

I would now like to turn the call over to David Arrington, Vice President of Investor Relations and Corporate Affairs. Please go ahead.

David Arrington
Coherus BioSciences, Inc. - VP of IR & Corporate Affairs

Thank you, May, and good afternoon, everyone. After close of market today, we issued a press release on our fourth quarter and year-end financial results. This release can be found on the Coherus BioSciences website. Joining me for today's call will be Denny Lanfear, Coherus' CEO; Dr. Jean Viret, Chief Financial Officer; Vince Anicetti, Chief Operating Officer; and Thomas Fitzpatrick, Chief Legal Officer.

Before we begin our formal remarks, I would like to remind you that we will be making forward-looking statements with respect to product

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot